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Abstract The nematode Capillaria aerophila (Trichuroi-
dea, Trichuridae) affects the respiratory system of cats and
other animals and occasionally of human beings. Infected
cats may show bronchovesicular sounds, inflammation,
sneezing, wheezing and, chronic cough and, sometimes,
bronchopneumonia and respiratory failure. The present
study evaluated the efficacy and safety of the antiparasitic
spot-on formulation containing imidacloprid 10 %/moxidec-
tin 1 % (Advocate®, Bayer Animal Health) in the treatment
of natural feline infection with the lungworm C. aerophila.
The efficacy of Advocate® administered once was tested on
days 7±1 and 11±1 following treatment at day 0 and com-
pared to faecal egg counts on days −6±1 and −2±1. Overall,
36 cats treated either with Advocate® (treatment group, n0
17 cats) or left untreated (control group, n019 cats) were
included in the study. Geometric means of faecal egg counts
values in eggs per gram of faeces were 124.03 prior to
treatment and 0.26 posttreatment in treatment group, while
107.03 and 123.94 pre- and posttreatment in the untreated
cats. Post-baseline egg counts showed a 99.79 % reduction
in Advocate®-treated animals in comparison with cats
which were left untreated. Also, treated cats showed no
adverse events. This trial demonstrated that Advocate®
spot-on formulation is safe and effective in the treatment
of feline lung capillariosis caused by C. aerophila.
Introduction
The antiparasitic spot-on formulation containing imidaclo-
prid 10 %/moxidectin 1 % (Advocate®, Bayer Animal
Health) is marketed for the treatment of different ecto- and
endoparasites affecting cats. The neonicotinoid imidacloprid
is an insecticide, while moxidectin is an endectocide mac-
rocyclic lactone with a broad-spectrum of activity. There-
fore, Advocate® can be applied dermally in cats for the
effective and safe control and/or prevention of a range of
major internal (i.e. hookworms, roundworms and heart-
worms) and external (i.e. mites, fleas) parasites. As key
examples, this formulation has shown to be highly effective
in the treatment of feline otocariosis (Fourie et al. 2003) and
can be used safely even in cats heavily infected with adult
Dirofilaria immitis (Arther et al. 2005). Also, a recent ex-
perimental study has demonstrated the high efficacy and
safety of Advocate® for the treatment of feline respiratory
infection caused by the metastrongylid lungworm Aeluros-
trongylus abstrusus (Traversa et al. 2009a).
Along with A. abstrusus, Capillaria aerophila (Trichur-
oidea, Trichuridae) is another nematode affecting the lungs
of cats. The adult stages live embedded in the respiratory
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epithelium of bronchioles, bronchi and trachea of the defin-
itive host, i.e. cats, dogs, wild carnivores and occasionally
humans. The parasites damage the lung parenchyma and
induce chronic bronchitis characterised by symptoms of
varying severity, i.e. bronchovesicular sounds, inflamma-
tion, sneezing, wheezing, and chronic dry or moist and
productive (i.e. especially when bacterial complications oc-
cur) cough; when the parasite burden is heavy, the diseases
can lead to mortality due to bronchopneumonia and respi-
ratory failure (Holmes and Kelly 1973; Bowman et al. 2002;
Taylor et al. 2007; Burgess et al. 2008; Traversa et al.
2009b).
The infection caused by C. aerophila is still underesti-
mated, albeit the nematode is globally distributed and ap-
parently spreading in different countries; moreover, it may
cause relevant clinical pictures and has a certain zoonotic
potential (Lalosević et al. 2008; Conboy 2009; Traversa et
al. 2010). In the past few years, gaps have been filled on its
morphology and biology (Traversa et al. 2011), epidemiol-
ogy (Traversa et al. 2009b; Di Cesare et al. 2011), molecular
diagnosis (Di Cesare et al. 2012a) and genetic make-up (Di
Cesare et al. 2012b). Nevertheless, information on effective
and safe anthelmintic therapy of pulmonary capillariosis is
almost non-existent and those scanty information published
are related to few single clinical cases. Given the significant
merit in establishing reliable protocols for the therapy of the
infection caused by C. aerophila, the aim of the present
study was to evaluate the efficacy and safety of Advocate®




The study was carried out from July 2009 to October 2011
as a controlled, randomised, multicentric field trial in accor-
dance to Good Clinical Practice by the European Agency for
the Evaluation of Medicinal Products (CVMP/VICH GL7,
July 2000; CVMP/VICH GL19, July 2001).
The blinded investigator laboratory (site A) was the Par-
asitology Laboratory at the Department of Comparative
Biomedical Sciences, University of Teramo, Italy. Seven
veterinary practices in central Italy were in charge for the
enrolment of the cats (see Acknowledgments). The practices
were designated as site B (located in Isola del Gran Sasso
Municipality, Abruzzo region), site C (Pescara Municipality,
Abruzzo region), sites D and H (Ascoli Piceno Municipality,
Marche region), site E (Teramo Municipality, Abruzzo re-
gion), site F (Castelnuovo Vomano Municipality, Abruzzo
region) and site G (Alba Adriatica Municipality, Abruzzo
region).
After a pre-inclusion selection via a qualitative faecal
examination, positive animals underwent two pretreatment
quantitative copromicroscopic examinations at days −6±1
and −2±1, a clinical examination at anthelmintic treatment
(day 0) and two posttreatment quantitative copromicro-
scopic examinations at days 7±1 and 11±1.
Pre-inclusion screening
Five hundred and forty-two cats, i.e. 107, 125, 75, 32, 101,
27 and 75 in sites B–G, respectively, were subjected to a
screening examination for C. aerophila eggs by a qualitative
copromicroscopic examination by two different floatation
procedures employing a sugar solution with a 1.200 specific
gravity (s.g.) and a 1.350 s.g. zinc sulphate solution (Sloss et
al. 1994).
Eggs of C. aerophila (Fig. 1) were identified at the
species level by the characteristic size, shape, plug morphol-
ogy and appearance of the egg shell (Traversa et al. 2011).
All cats with positive results for C. aerophila at this screen-
ing were further evaluated by inclusion and exclusion crite-
ria for the enrolment in the study.
Inclusion and exclusion criteria
Animals which scored positive for eggs of C. aerophila at
the pre-inclusion were subjected to two quantitative copro-
microscopic examinations with a McMaster method (Sloss
et al. 1994) at days −6±1 and −2±1 to evaluate the pretreat-
ment values of egg per gram of faeces (EPG). Inclusion
criteria were:
– Cats positive at least at one of the above four
examinations;
– Cats ageing more than 9 weeks
– Cats weighing more than 1 kg
Fig. 1 Eggs of C. aerophila. Scale bar, 20 μm
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Animals which met these criteria were enrolled with the
owner's consent to participate in the study. The study was
continued only if the animals were considered suitable for
the study when examined physically on day 0 (treatment).
Cats could be excluded according to the following exclu-
sion criteria:
– Negativity at the two pre-inclusion quantitative
examinations;
– Cats treated within the last 2 months with any anthel-
mintic drug, including macrocyclic lactones;
– Pregnant or lactating queens;
– Cats with severe systemic diseases and/or with a general
bad health.
Anthelmintic treatment
Of the 542 screened cats, 36 (6.6 %) animals from 6 sites
were infected and recruited. Specifically, 13 come from site
B (12.1 % of cats screened in the Site), 1 from site C
(0.8 %), 2 from site D (2.6 %), 6 from sites E (18.7 %)
and F (5.9 %) each, and 8 from site H (10.6 %). Site G
enrolled no positive animals in the study. At day 0, the
animals were clinically examined prior to treatment and then
allocated to two groups, one treated (treatment group) with
the spot-on solution containing imidacloprid 10 %/moxidec-
tin 1 % (Advocate®) and one left untreated (control group),
as per a randomised block design in a ratio of 1:1.
Cats in the first group were treated with Advocate® spot-
on solution as single dosage applied according to label
instructions, while animals in the control group did not
receive any compound till the end of the study. All control
cats received a rescue dose of Advocate® after the comple-
tion of the study.
A complete clinical examination was performed post-
treatment to evaluate safety of the treatment and potential
adverse events. The occurrence of adverse events (AE)
could be registered, considering definitions accordingly to
the Good Clinical Practice guidelines (CVMP/VICH GL9,
July 2000).
Posttreatment evaluation
Faecal samples collected from the 36 cats at days 7±1
and 11±1 were subjected to two quantitative McMaster
examinations. Primary efficacy criterion was the reduc-
tion of post-baseline EPG faecal egg counts. The high-
est value from the four egg counts performed in the
pretreatment assessment (i.e. two examinations at days
−6±1 and −2±1) was used as baseline value. From the
four faecal egg counts performed posttreatment, the
highest value was used for the calculation of efficacy.
The analysis of the efficacy criterion was performed on
the log-transformed scale using an analysis of covari-
ance adjusted for baseline egg counts. Geometric means
were calculated as: Gmean 0 e
AML − 1, where AML 0
the arithmetic mean of the EPG counts. The difference
between the geometric mean (GM) of EPG before and
after treatment was determined and expressed as an
efficacy value using the following formula: efficacy %
0 100 × (GM pretreatment − GM posttreatment)/GM
pretreatment. The percentage decrease was considered
effective if efficacy was at least 90 %.
Results
All enrolled 36 cats completed the study according to the
protocol. They were appropriately treated, no cats were
removed from the study subsequent to inclusion for any
reason and all of them were included in efficacy
calculations.
Pretreatment egg counts
Geometric means of EPG at baseline were 124.03 (arithme-
tic mean 152.9±128.1) in the Advocate® and 107.03 (arith-
metic mean 118.4±53.3) in the untreated control group. No
statistically significant (P00.568) differences in egg counts
in pretreatment period between the two groups were found.
Efficacy evaluation
In the treatment group, EPG value was reduced from 152.9
(±128.1) at baseline to 2.9 (±12.1) at day 7 or 11. In the
untreated animals, an increase from 118.4 (±53.3) to 163.2
(±165.7) EPG was found. Geometric means of EPG were
124.03 (baseline) and 0.26 (posttreatment) in the treatment
group and 107.03 (baseline) and 123.94 (posttreatment) in
the control cats. Relative change from baseline was 99.79
and −15.8 % in the treated and control cats, respectively
(Table 1). The difference between groups in change from
baseline was 4.672 (95 % confidence interval from 4.128 to
5.216) which is statistically significant at P<0.0001, thus
showing superiority of Advocate® spot-on compared to the
untreated group.
Adverse events, clinical income and outcome
No AEs were recorded in any of the treated cats. Clinical
symptoms were present prior to treatment (day 0) in three
cats, thus were not considered to be related to the study
medication. More specifically, at clinical examination, three
animals showed cough due to capillariosis and a concomi-
tant infection by A. abstrusus (i.e. two cats belonging to
treatment group in site E), and cough due to C. aerophila
Parasitol Res (2012) 111:1793–1798 1795
and diarrhoea of unknown origin (i.e. one cat from untreated
control group from site F).
At completion of the study, all 36 enrolled cats but one
were clinically healthy. Specifically, respiratory distress dis-
appeared in the two symptomatic cats from site E while
cough was still present in the untreated cat of the control
group. However, in this cat, cough disappeared after rescue
treatment at study completion.
Discussion
This study demonstrated that a single administration of
Advocate® spot-on at a minimum dose per kilogram body
weight of 10 mg imidacloprid and 1 mg moxidectin is safe
and effective in the treatment of feline infection by C.
aerophila under field conditions. The efficacy of this anthel-
mintic formulation was investigated on the basis of copro-
microscopic results. Indeed, a modified quantitative
McMaster method was selected to determine the pre- and
posttreatment infection status (Sloss et al. 1994) of the cats
recruited for the study. Even though a sensitivity <100 %
cannot be ruled out, if compared with necropsy or experi-
mental molecular assays, the use of this method still is the
most reliable approach to detect C. aerophila eggs and, for
this reason, it was chosen for the success criteria in the
study. The diagnostic sensitivity of the test, and thus the
reliability of the data obtained, was assured by two consec-
utive quantitative examinations repeated twice at each of the
pre- and posttreatment sample collection. Furthermore, the
identification of C. aerophila ova in positive samples was
carefully performed with no risks of misidentification. In
fact, while barrel/lemon-like eggs found in faeces of dogs
require a thorough morphometric and morphological analy-
sis to avoid misdiagnosis with other trichuroids, e.g. Capil-
laria boehmi or Trichuris vulpis (Traversa et al. 2011), these
eggs are usually not a diagnostic problem for cats. Indeed,
feline whipworms (i.e., Trichuris felis, Trichuris campanula
and Trichuris serrata), regardless they are separate species
or the same, debated, parasite (Cameron 1937; Ng and Kelly
1975; Bowman et al. 2002), are only confined in few areas
of the Americas and few other regions, where they have
been reported very rarely in the last 40 years (Kelly 1973;
Ng and Kelly 1975; Hass and Meisels 1978; Bowman et al.
2002; Castro et al. 2009). Although morphological and
morphometrical studies of feline trichuroids are few and
old (Kelly 1973; Ng and Kelly 1975; Hass and Meisels
1978), the diagnosis of feline lung capillariosis is easy for
the almost null possibility to find whipworm eggs in feline
faeces and for the recently clarified diagnostic features of C.
aerophila ova (Traversa et al. 2011).
At the time the study starts, there was no drug licensed
with C. aerophila as an indication for use in cats. Addition-
ally, information on the field efficacy of parasiticides in the
treatment of the feline infection by C. aerophila are frag-
mentary and in most cases related to single clinical cases.
The repeated administration of dichlorvos was unsuc-
cessful in treating clinical signs and stopping egg shedding
in an infected cat. Then, the same cat was treated with
injectable levamisole at a dosage of 7.5 mg/kg for two
Table 1 Efficacy calculation of Advocate® against C. aerophila infection in treatment (n017 cats) and control groups (n019 cats)
Treatment group (Advocate®) Control group (untreated)
Study period and statistics Actual Change Actual Change Differencea B − A
Baseline EPG
Mean (SD) 152.9 (128.1) 118.4 (53.3)
95 % CL 87.1; 218.8 92.8; 144.1




Mean (SD) 2.9 (12.1) −150.0 (128.7) 163.2 (165.7) 44.7 (139.3) 170.98 (118.84)
95 % CL −3.3; 9.2 −216.2; −83.8 83.3; 243 −22.4; 111.9 88.90; 253.07
Min to max 0 to 50 −600.0 to −50.0 50 to 800 −50.0 to 600 F017.9595
Median 0.0 −100.0 150.0 0.0 P00.0002
Gmean 0.26 99.79 % 123.94 −15.8 %
Maximum actual counts of faecal egg count in terms of C. aerophila eggs per gram of faeces (EPG) pretreatment (baseline, days −6±1 and −2±1)
and post-baseline (days 7±1 and 11±1) and change from baseline are indicated. Mean and standard deviation (SD), 95 % confidence level (CL),
minimum (min), maximum (max), median and geometric mean of EPG values are also reported
a Difference and 95 % CI form ANOVA adjusted for baseline
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consecutive days, repeated as a single administration after
2 weeks. This protocol has shown effect in reducing clinical
signs and egg shedding (Endres 1976). The same molecule
has been used in another single case at the oral dose of 5 mg/
kg for five consecutive days, administered three times, with
intervals of 9 days between treatments. At day 30 after the first
administration, clinical signs disappeared and at days 40 and
150 the animal scored negative upon copromicroscopic
examinations (Norsworthy 1975). However, this report can
be questioned by the evaluation of the therapy, stated to have
relied on the detection of eggs and larvae of C. aerophila by a
Baermannmethod. Actually, larvalC. aerophila are not found
in fresh faeces, given that the eggs embryonate not before
1 month after emission (Traversa et al. 2011).
With regard to macrocyclic lactones, two off label subcu-
taneous administrations of 300 μg/kg of abamectin 14 days
apart have led to reduction of cough and nasal discharge in an
infected cat, which also became negative at the faecal exam-
ination (Barrs et al. 2000). The efficacy of ivermectin against
different endoparasites has been evaluated in a study carried
out in 24 naturally infected cats. Two of these animals, which
were treated orally with ivermectin either at 100 or 300 μg/kg,
scored copromicroscopically positive for Capillaria spp. after
treatment with the former and negative at copromicroscopy
and necropsy with the latter; however, these data were stated
to be too limited to infer any conclusion on the efficacy of
ivermectin against Capillaria spp. (Blagburn et al. 1987).
The present study fills an important gap in treatment
options for lung capillariosis in cats, in that the macrocyclic
lactone moxidectin present in the Advocate® spot-on for-
mulation proved to be effective against C. aerophila in a
number of infected cats. In general, the single application of
Advocate® at the recommended dosage leads to a high
moxidectin concentration and long elimination half-life,
which provide a prolonged activity against major feline
parasites. After the recent experimental demonstration that
Advocate® is effective against the major cat lungworm A.
abstrusus (Traversa et al. 2009a), the present study allows to
include another respiratory nematode affecting cats, C. aero-
phila, among the feline parasitic nematodes that can be
effectively and safely treated by this spot-on.
For its safety and efficacy, Advocate® can be considered
a suitable choice for the treatment of cat lung capillariosis.
Also, this formulation overcomes the constraints of para-
siticides with a certain efficacy against C. aerophila, which
have been applied off label and/or in oral or parenteral
formulations even in repeated dosages. In fact, the use of
oral anthelmintics in feline clinical practice is often impaired
by difficulties of the administration to indocile or feral
animals and the need of multiple dosing. Indeed, Advocate®
has advantages in the current practice for the treatment of cat
capillariosis, i.e. the possibility of a single dose and the
easy-to-apply spot-on administration.
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